According to a new report, published by KBV research, The Global Veterinary Biomarkers Market size is expected to reach $1.5 billion by 2028, rising at a market growth of 11.7% CAGR during the forecast period.
The Production segment is showcasing a CAGR of 13.3% during (2022 - 2028). This growth is due to an increase in the population of livestock and other producing animals in developing nations. Additionally, the rising incidence of dangerous infectious diseases like tuberculosis in animals used for production poses a serious threat to the expansion of many diagnostic techniques.
The Inflammatory & Infectious Diseases segment acquired maximum revenue share in the Global Veterinary Biomarkers Market by Disease Type in 2021 thereby, achieving a market value of $548.4 million by 2028. This is because both companion and farm animals are increasingly susceptible to numerous infectious illnesses. In several nations, different diagnostic approaches have been developed in response to the government's desire to stop the spread of zoonotic diseases from animals to people.
The Biomarker Readers segment has shown the growth the rate of 14% during (2022 - 2028). The primary cause of this is the rising rate of diagnoses in veterinary clinics. The major players have introduced specific veterinary biomarker readers because human biomarker readers are not precise and calibrated for animal readings.
The Disease Diagnostics segment is generating highest revenue share in the Global Veterinary Biomarkers Market by Application in 2021 thereby, achieving a market value of $762.8 million by 2028. This is due to the rise of veterinary admissions for disease detection in both industrialized and developing nations. With the demand for safer & more efficient medications growing together with the desire for expensive specialist therapies, disease diagnostics has a lot of potentials.
The North America market dominated the Global Veterinary Biomarkers Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $544.9 million by 2028. The Europe market is exhibiting a CAGR of 10% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 12.6% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/veterinary-biomarkers-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Zoetis, Inc., Merck & Co., Inc., Virbac, IDEXX Laboratories, Inc., MI:RNA Diagnostics Ltd., Mercodia AB, Antech Diagnostics, Inc. (Mars, Inc.), Avacta Animal Health Limited (Vimian Group), Life Diagnostics, Inc., and Acuvet Biotech.
By Animal Type
By Disease Type
By Product Type
By Application
By Geography
Companies Profiled
Unique Offerings 
